Trial Profile

Comparative Effects of Empagliflozin Versus Glimepiride After 26-weeks of Treatment Add on Metformin on Myocardial Metabolic Rate of Glucose Estimated Through 18FDG-PET in Patients With Type 2 Diabetes

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 14 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Empagliflozin (Primary) ; Glimepiride
Indications Coronary disorders; Ischaemic heart disorders; Type 2 diabetes mellitus
Focus Pharmacodynamics
Acronyms FIORE

01 Dec 2022 Results published in the Diabetes, Obesity and Metabolism
14 Nov 2022 Primary endpoint (Change of myocardial metabolic rate of glucose) has been met according to results published in the Diabetes, Obesity and Metabolism
27 Dec 2021 Status changed from recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com